Designated Targets. If Roche selects a Target which is not a Blocked Target and such Target is cleared through the Novartis ROFO mechanism, Roche has non-exclusive rights within the scope of its basic license grant to develop and commercialize RNAi Products directed to such “Designated Target” in the Field.
Appears in 4 contracts
Samples: License and Collaboration Agreement (Regulus Therapeutics Inc.), License and Collaboration Agreement (Regulus Therapeutics Inc.), License Agreement (Isis Pharmaceuticals Inc)
